News | Breast Imaging | May 26, 2020

Opto-acoustic mesoscopy visualizes tumor tissue patterns

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of pol

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of polyethylene microspheres (diameter, 20 μm) dispersed in agar. The inset shows a zoomed-in view of the region boxed with a yellow dashed line. In addition, the yellow boxes are signal profiles along the xy and z axes across the microsphere centre, as well as the corresponding full width at half-maximum values. c Normalized absorption spectra of Hb, HbO2 and gold nanoparticles (AuNPs). The spectrum for the AuNPs was obtained using a USB4000 spectrometer (Ocean Optics, Dunedin, FL, USA), while the spectra for Hb and HbO2 were taken from http://omlc.org/spectra/haemoglobin/index.html. The vertical dashed lines indicate the five wavelengths used to stimulate the three absorbers: 710, 750, 780, 810 and 850 nm. Optoacoustic signals were filtered into a low-frequency band (red) and high-frequency band (green), which were used to reconstruct separate images.


May 26, 2020 — Breast cancer is the most common cancer in women. But individual tumors can vary significantly, presenting different spatial patterns within their mass. Researchers at the Technical University of Munich (TUM) and Helmholtz Zentrum München have now succeeded in visualizing spatial changes within tumors by means of optoacoustics. This method may be helpful for the future development of new drugs.

Malignant tumors consume nutrients and oxygen faster than healthy cells. To do so, they recruit blood vessels in their environment. Depending on tumor type and genetic profile, there are differences on how tumors look internally. Typically, tumors present different patterns across their volume. The role of this spatial heterogeneity is not well understood or studied in living tumors. Typically used to understand biological functions in tumors, optical microscopy, for example, gives limited insights into the spatial heterogeneity of tumors as it only accesses volumes of less than a cubic millimeter.

High resolution with new imaging method

A new technique developed by Munich researchers, known as multi-spectral optoacoustic mesoscopy (MSOM), has now been shown capable of resolving optical contrast through tumor volumes that are at least 1,000 times larger than those possible with optical microscopy, enabling high-resolution visualization of tumor heterogeneity patterns. With this imaging method, the tumor is first excited from all sides with pulses of infrared laser light. “Tumor and tissue components that absorb this excitation light undergo a tiny, transient temperature increase, which leads to a small local volume expansion, followed by a contraction. This expansion and contraction process generates a weak ultrasound signal, which we collect with a detector,” said guest researcher Jiao Li, M.D.

The data collected is mathematically processed to form light absorption images which indicate different tumor patterns reflecting tumor oxygenation and vascularization. “For the first time, MSOM offers optical images that reach inside tumors to depths of ten millimeters and more with a resolution of less than 50 micrometers,” said Li.

Understanding functional variety in tumors

“MSOM imaging of solid tumors allowed us to see tumors in a new light,” said Prof. Vasilis Ntziachristos, holder of the Chair of Biological Imaging at TUM and Director of the Institute for Biological and Medical Imaging at Helmholtz Zentrum München. “MSOM allows us to understand how tumor functionality varies across the tumor, clearly moving the reach of optical observations well beyond the depth penetration limitations of optical microscopy.”

In the pictures taken from mamma carcinomas of mice, researchers can see patterns indicating the presence or absence of blood vessels, and thus study blood supply patterns. MSOM can also resolve hemoglobin levels, and indicate whether oxygen is bound to hemoglobin or not. Furthermore, MSOM images were used to determine permeability of the vessel walls relative to nanoparticles. Using the mouse model, the scientists were already able to track how tiny gold particles were transported.

3-D tumor pictures without surgical biopsy

In contrast to conventional histology, where tissue has to be removed, cut up and examined under the microscope by a pathologist, MSOM allows a three-dimensional analysis of entire living tumors without the need for surgical biopsies. This further supports longitudinal studies so that tumor growth or recession under different drugs can be studied with greater accuracy. All of which paves the way for an improved understanding of biological function and drug efficacy during drug development for humans.

For more information: www.tum.de/


Related Content

News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | FDA

Dec. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT, has announced ...

Time December 04, 2025
arrow
News | Women's Health

Dec. 1, 2025 — ScreenPoint Medical has completed a commercial agreement making its Transpara breast-imaging AI portfolio ...

Time December 03, 2025
arrow
News | Mammography

Nov. 30, 2025 — At RSNA 2025, Siemens Healthineers will introduce new capabilities for its Mammomat B.brilliant ...

Time December 02, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Women's Health

Dec. 1, 2025 — A study of data from seven outpatient facilities in the New York region found that 20-24% of all the ...

Time December 02, 2025
arrow
News | Mammography

Nov. 26, 2025 — GE HealthCare has announced it received FDA Premarket Authorization for Pristina Recon DL, an advanced ...

Time November 29, 2025
arrow
News | Artificial Intelligence

Nov. 25, 2025 – Medical imaging AI company Avicenna.AI has announced a strategic partnership with Ferrum, an AI ...

Time November 25, 2025
arrow
News | Ultrasound Imaging

Nov. 12, 2025 — GE HealthCare and DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., have announced their ...

Time November 20, 2025
arrow
News | Breast Imaging

Nov. 17, 2025 — RadNet, Inc. and its wholly owned subsidiary, DeepHealth have announced results from the largest real ...

Time November 17, 2025
arrow
Subscribe Now